急性缺血性脑卒中(AIS)是一种严重影响人类健康相关的疾病,其拥有高发病率和高死亡率,并与吸烟、高脂饮食等不良生活习惯相关,人工智能(AI)比如机器学习(ML)和深度学习(DL),可以实现从临床及辅助检查尤其是成像学检查中提取特征数据,经过算法处理,得出可信结果。近几年AI更多地应用于医院系统的工作中,并成为临床工作及科研项目有力的帮手。本文全面综述了AI预测急性缺血性脑卒中(AIS)患者在经过血管内治疗,尤其是经过血栓切除术治疗后的预后情况,从而实现精准有效的临床管理和护理决策。此外,本文还批判性地评估了现有研究的局限性,并且指出了新的研究方向,最终目标是提高AIS患者的生存率。Acute ischemic stroke (AIS) is a serious human health-related disease that is characterized by elevated morbidity and mortality rates. It is often linked to detrimental lifestyle behaviors, including smoking and high-fat dietary intake. The advent of artificial intelligence (AI), encompassing machine learning (ML) and deep learning (DL) methodologies, facilitates the extraction and analysis of feature data derived from clinical and ancillary assessments, particularly imaging studies. These data are processed through sophisticated algorithms to yield reliable outcomes. In recent years, AI has been increasingly integrated into hospital systems, emerging as a formidable tool in both clinical practice and research initiatives. This paper presents a comprehensive analysis of AI applications in predicting the prognosis of acute ischemic stroke (AIS) patients following endovascular interventions, with a particular focus on thrombectomy procedures. The objective is to enhance the accuracy and efficacy of clinical management and care decision-making processes. Furthermore, the study critically examines the limitations inherent in current research and identifies prospective avenues for future investigation, ultimately aiming to improve the survival outcomes of AIS patients.
Objective To observe engraftment kinetics, the incidence and severity of graft-versus-host disease (GVHD), and clinical outcome on 40 recipients undergoing allogeneic peripheral blood stem cell transplantation (allo-P...
详细信息
Objective To observe engraftment kinetics, the incidence and severity of graft-versus-host disease (GVHD), and clinical outcome on 40 recipients undergoing allogeneic peripheral blood stem cell transplantation (allo-PBSCT).Methods From June 1997 to May 1999, forty leukemia patients with a median age of 35 years underwent allo-PBSCT. PBSC were mobilized with G-CSF at a dose of 5 μg/kg s.c. every 12 hours for 5 days. A median of 7.7 (2.0 - 16.8) × 106 CD34+ cells/kg was infused into the recipients. Busulfancyclophosphamide (BU-CY) was used as the conditioning regimen. All patients received cyclosporine A and either methotrexate ( n = 34) or methylprednisolone ( n = 6) for GVHD *** Engraftment of neutrophils and platelets was achieved at a median of 13 days (9- 28 days) and 12 days (7- 60 days) respectively. Patients receiving ≥4×106 CD34+ cells/kg or given G-CSF post transplant had significantly accelerated neutrophil and platelet engraftment. Acute GVHD occurred in 17 of 40 patients (42.5%), with grade Ⅱ-Ⅳ acute GVHD in 10 patients (25%). Chronic GVHD developed in 21 (9 extensive, 12 limited) out of 30 evaluable patients (21/30, 70%) with a median follow up of 380 days (180-900 days). Transplant related mortality was 17.5% end the relapse rate was 10%. The probability of leukemia free survival at 3 years was 72.5%.Conclusion Allo-PBSCT can provide rapid hematopoietic reconstitution without an increased incidence of acute GVHD, but may be associated with a high risk of chronic GVHD.
暂无评论